Female (1,292); Male (1,419); Not Reported (473)

0 to 4 years (1,010); 5 to 9 years (626); 10 to 14 years (627); 15 to 19 years (403); 20 to 24 years (19); Pediatric and Young Adult (<40 years) (499)

Asian (3); Black or African American (404); Native Hawaiian or Other Pacific Islander (1); White (2,271); Not Reported (505)

Hispanic or Latino (54); Not Hispanic or Latino (2,647); Not Reported (483)

Acinar Cell Carcinoma (1); Acute Leukemias of Ambiguous Lineage (1); Acute Lymphoblastic Leukemia, NOS (450); Acute Myeloid Leukemia (46); Acute Myeloid Leukemia, Core Binding Factor (12); Acute Myeloid Leukemia, KMT2A rearrangement (2); Acute Myelomonocytic Leukemia (2); Acute Promyelocytic Leukemia (10); Acute Promyelocytic Leukemia, PML-RARA (1); Adenocarcinoma, NOS (3); Adrenocortical Carcinoma (2); Alveolar Rhabdomyosarcoma (10); Alveolar Soft Part Sarcoma (9); Anaplastic Large Cell Lymphoma (5); Angiomatoid Fibrous Histiocytoma (1); Astrocytoma, NOS (26); Atypical Meningioma (1); B-cell Acute Lymphoblastic Leukemia, DUX4-IGH (7); B-cell Acute Lymphoblastic Leukemia, DUX4-IGH like (1); B-cell Acute Lymphoblastic Leukemia, ETV6-RUNX1 (14); B-cell Acute Lymphoblastic Leukemia, ETV6-RUNX1 like (1); B-cell Acute Lymphoblastic Leukemia, Hyperdiploidy (10); B-cell Acute Lymphoblastic Leukemia, Hypodiploidy (3); B-cell Acute Lymphoblastic Leukemia, iAMP21 (2); B-cell Acute Lymphoblastic Leukemia, KMT2A rearrangement (4); B-cell Acute Lymphoblastic Leukemia, NOS (334); B-cell Acute Lymphoblastic Leukemia, NUTM1 rearrangement (1); B-cell Acute Lymphoblastic Leukemia, PAX5 alteration (1); B-cell Acute Lymphoblastic Leukemia, TCF3-PBX1 (10); B-cell Acute Lymphoblastic Leukemia, TCF3-PBX1; High-Grade Glioma, NOS (1); Basal Cell Carcinoma (1); Botryoid Type Embryonal Rhabdomyosarcoma (2); Burkitt Lymphoma (52); Carcinoma, NOS (1); Central Neurocytoma (2); Chondroblastic Osteosarcoma (1); Chondrosarcoma (3); Choriocarcinoma (2); Choroid Plexus Carcinoma (2); Chronic Myeloid Leukemia (2); Clear Cell Sarcoma of Kidney (2); Congenital Mesoblastic Nephroma (5); Control Sample (320); Craniopharyngioma, NOS (22); Dermatofibrosarcoma Protuberans (4); Desmoid/Aggressive Fibromatosis (1); Desmoplastic Small Round Cell Tumor (1); Desmoplastic/Nodular Medulloblastoma (6); Diffuse Large B-cell Lymphoma, NOS (52); Dysembryoplastic Neuroepithelial Tumor (2); Dysgerminoma (9); Embryonal Carcinoma, NOS (7); Embryonal Rhabdomyosarcoma (53); Endometrioid Adenocarcinoma, NOS (1); Ependymomal Tumor (23); Ependymomal Tumor, Posterior Fossa (7); Ependymomal Tumor, Supratentorial (1); Epithelioid Hemangioendothelioma (2); Epithelioid Sarcoma (4); Ewing Sarcoma (64); Fibrillary Astrocytoma (2); Fibroblastic Osteosarcoma (1); Fibrosarcoma, NOS (4); Follicular Thyroid Cancer (1); Gangliocytoma (2); Ganglioglioma (3); Ganglioneuroblastoma (26); Ganglioneuroma (1); Germ Cell Tumor, NOS (5); Germinoma (16); Giant Cell Tumor, NOS (3); Glioblastoma (1); Granulosa Cell Tumor (3); Hepatoblastoma (16); Hepatocellular Carcinoma (1); High-Grade Glioma, NOS (32); Hodgkin Lymphoma (30); Infantile Fibrosarcoma (3); Langerhans Cell Histiocytosis (19); Leiomyosarcoma, NOS (2); Liposarcoma (3); Liver Malignancy, NOS (2); Low-Grade Glioma, NOS (15); Lymphocyte-Depleted Classical Hodgkin Lymphoma (3); Lymphocyte-Rich Classical Hodgkin Lymphoma (25); Malignant Fibrous Histiocytoma (7); Malignant Mesenchymoma (3); Malignant Mesenchymoma of the Liver (1); Malignant Peripheral Nerve Sheath Tumor (8); Medulloblastoma (65); Medulloepithelioma (1); Melanoma (17); Mesenchymal Chondrosarcoma (1); Miscellaneous Brain Tumor (26); Mixed Cellularity Classical Hodgkin Lymphoma (79); Mixed Germ Cell Tumor, Brain (1); Mixed Germ Cell Tumor, NOS (3); Mucinous Adenocarcinoma, NOS (2); Mucoepidermoid Carcinoma (2); Mycosis Fungoides (2); Myxopapillary Ependymoma (2); Nasopharyngeal Carcinoma (19); Neuroblastoma (106); Neuroepithelioma (21); Nodular Lymphocyte-Predominant Hodgkin Lymphoma (4); Nodular Sclerosis Classical Hodgkin Lymphoma (213); Non-Hodgkin Lymphoma (99); Oligodendroglioma (8); Osteosarcoma (100); Papillary Ependymoma, NOS (1); Paraganglioma (2); Parosteal Osteosarcoma (3); Periosteal Osteosarcoma (1); Peripheral Primitive Neuroectodermal Tumor (2); Pilocytic Astrocytoma (43); Pineoblastoma (1); Pleomorphic Xanthoastrocytoma (3); Pleuropulmonary Blastoma (1); Primitive Neuroectodermal Tumor (1); Renal Cell Carcinoma (3); Retinoblastoma (92); Rhabdomyosarcoma (35); Serous Surface Papillary Carcinoma (1); Small Cell Osteosarcoma (1); Soft Tissue Sarcoma, NOS (10); Solid Cancer of Unknown Primary (3); Solitary Fibrous Tumor/Hemangiopericytoma (3); Spindle Cell Rhabdomyosarcoma (1); Spindle Cell Sarcoma, NOS (1); Squamous Cell Carcinoma, NOS (1); Subependymal Giant Cell Astrocytoma (1); Synovial Sarcoma (17); T-cell Acute Lymphoblastic Leukemia, KMT2A rearrangement (1); T-cell Acute Lymphoblastic Leukemia, NOS (69); Telangiectatic Osteosarcoma (3); Teratocarcinoma (2); Teratoma, NOS (12); Wilms (194); Yolk Sac Tumor, NOS (21); Not Reported (21)

Not Reported (3,184)

Targeted Sequencing (3,184); Whole Genome Sequencing (8)